Frankfurt
19.08.25 | 08:03
1,782 Euro
0,00 % 0,000
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 16.07. | Orexo Q2 2025 slides: Maintains full-year outlook despite FX headwinds | 1 | Investing.com | ||
| 16.07. | Orexo hält trotz Währungsgegenwind an Jahresprognose für 2025 fest | 1 | Investing.com Deutsch | ||
| OREXO Aktie jetzt für 0€ handeln | |||||
| 16.07. | Orexo AB: Orexo Q2 2025 Interim Report | 120 | GlobeNewswire (Europe) | 2025 outlook remains amid currency headwinds and non-recurring effectQ2 2025 highlights› Total net revenues of SEK 118.2 m (154.0), including a non-recurring rebate payment of SEK 8.9 m› EBITDA of SEK... ► Artikel lesen | |
| 02.06. | Orexo to present clinical data for OX640 at the EAACI Congress | 243 | PR Newswire | OX640 is a nasal rescue medication with powder-based epinephrine for the treatment of severe allergic reactions (including anaphylaxis) and is based on the proprietary AmorphOX® technologyEAACI... ► Artikel lesen | |
| 06.05. | Orexo Q1 2025 slides: stable revenue growth amid pipeline advancements | 1 | Investing.com | ||
| 06.05. | Orexo AB: Orexo Q1 2025 Interim Report | 157 | GlobeNewswire (Europe) | Q1 2025 highlights› Total net revenues of SEK 146.2 m (139.3)› EBITDA of SEK 5.9 m (15.9)› Net earnings of SEK -15.9 m (-8.9)› US Commercial segment net revenues of SEK 133.0 m (129.3), in local currency... ► Artikel lesen | |
| 10.04. | Orexo announces positive data for powder-based intranasal vaccine formulated with the AmorphOX technology | 376 | PR Newswire | The study was conducted in partnership with Abera Bioscience, a platform and vaccine developer with over 30 years of research in the medical, molecular and microbiological fields.Both formulations... ► Artikel lesen | |
| 06.02. | Orexo AB: Orexo Interim Report Q4 2024, incl. Full Year Report | 159 | GlobeNewswire (Europe) | Q4 2024 highlights› Total net revenues of SEK 160.3 m (166.0)› EBITDA of SEK 28.9 m (12.4)› Impairment of intangible assets Deprexis® of SEK 71.1 m (0) and Vorvida® of SEK 28.1 m (0)› Net earnings of... ► Artikel lesen | |
| 10.01. | Orexo announces positive topline data from clinical study of OX640 in subjects with and without allergic rhinitis | 460 | PR Newswire | OX640 is a nasal rescue medication with powder-based epinephrine for the treatment of allergic reactions (incl. anaphylaxis) and is based on the proprietary AmorphOX® technology.The clinical... ► Artikel lesen | |
| 17.12.24 | Orexo enters into collaboration with Abera to develop nasal powder vaccines based on the AmorphOX technology | 495 | PR Newswire | The collaboration is in line with Orexo's strategy to broaden the use of its powder-based drug delivery technology AmorphOX®.Abera is a developer of mucosal vaccines and has several preclinical... ► Artikel lesen | |
| 02.12.24 | Orexo AB: Orexo and GAIA agree to terminate the partnership for Deprexis | 365 | GlobeNewswire (Europe) | Uppsala, Sweden - December 2, 2024 - Orexo AB (publ.), (STO:ORX) (OTCQX:ORXOY), today announces that Orexo AB and GAIA AG have decided to terminate the partnership agreement, covering the rights for... ► Artikel lesen | |
| 25.10.24 | Orexo initiates new study of OX640 in participants with allergic rhinitis | 357 | PR Newswire | OX640 is an intranasal rescue medication for the treatment of severe allergic reactions (incl. anaphylaxis) with powder-based epinephrine.OX640 is based on Orexo's proprietary drug delivery... ► Artikel lesen | |
| 24.10.24 | Orexo Interim Report Q3 2024 | 504 | PR Newswire | UPPSALA, Sweden, Oct. 24, 2024 /PRNewswire/ --
Q3 2024 highlights
› Total net revenues of SEK 136.5 m (156.1)
› EBITDA of SEK -0.7 m (-9.5)
› Net earnings of SEK -41.9... ► Artikel lesen | |
| 04.10.24 | Orexo's Nomination Committee for the Annual General Meeting 2025 | 369 | PR Newswire | UPPSALA, Sweden, Oct. 4, 2024 /PRNewswire/ -- The members of the Nomination Committee for the Annual General Meeting (AGM), that takes place on May 8, 2025, have been appointed and comprises... ► Artikel lesen | |
| 03.09.24 | Orexo to participate in Pareto Securities' 15th Annual Healthcare Conference 2024 | 358 | PR Newswire | UPPSALA, Sweden, Sept. 3, 2024 /PRNewswire/ -- Orexo AB (Publ.), (STO: ORX) (OTCQX: ORXOY), today announces the company will participate in Pareto Securities' 15th Annual Healthcare Conference... ► Artikel lesen |
15 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| AURORA CANNABIS | 4,095 | -6,61 % | BRISANTE Meldung setzt Aurora Cannabis Aktionäre unter Zugzwang. Bitte reagieren Sie jetzt sofort! | ||
| ABBVIE | 176,80 | -0,11 % | AbbVie Completes Acquisition of Capstan Therapeutics | Acquisition adds a potential first-in-class in vivo targeted lipid nanoparticle (tLNP) anti-CD19 CAR-T therapy candidate for B cell-mediated autoimmune diseases... ► Artikel lesen | |
| TILRAY BRANDS | 0,912 | -6,21 % | Tilray Brands +119%: Jetzt nehmen wir Gewinne mit! | Was für eine Rakete: Mein Cannabis-Tipp Tilray Brands geht sein meinem Tipp vor zehn Tagen steil und kann sich im Preis mehr als verdoppeln. Ist die Aktie jetzt zu heiß gelaufen? Perfektes Timing Der... ► Artikel lesen | |
| BRISTOL-MYERS SQUIBB | 41,515 | +0,50 % | Bristol Myers and SystImmune's lung cancer drug gets FDA boost | ||
| TEVA | 15,150 | -2,26 % | Teva Pharm: Gewinn übertrifft Erwartungen, doch Umsatzenttäuschung belastet die Aktie | ||
| VERTEX PHARMACEUTICALS | 339,00 | +1,44 % | Vertex Pharmaceuticals-Aktie: Kurs nur geringfügig im Minus (335,2656 €) | Der Kurs der dem Anteilsschein von Vertex Pharmaceuticals kommt kaum von der Stelle. Zuletzt zahlten Investoren für die Aktie 390,97 US-Dollar. Kaum auffällig ist aktuell an der Börse der Kurs von Vertex... ► Artikel lesen | |
| EYEPOINT PHARMACEUTICALS | 9,782 | +0,68 % | EyePoint Pharmaceuticals, Inc.: EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) |
WATERTOWN, Mass., Aug. 18, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients... ► Artikel lesen | |
| BAUSCH HEALTH | 6,659 | -3,07 % | Bausch Health Companies Inc.: Bausch Health Announces Increase in Shareholding by its Chairperson of the Board and Board Changes | LAVAL, QC / ACCESS Newswire / August 15, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) ("Bausch Health" or the "Company") today announced that Paulson Capital Inc. and certain affiliates and... ► Artikel lesen | |
| EDWARDS LIFESCIENCES | 67,78 | +0,98 % | Edwards Lifesciences-Aktie: Kurs heute im Minus (65,8386 €) | An der US-amerikanischen Börse liegt das Wertpapier von Edwards Lifesciences derzeit im Minus. Zuletzt zahlten Investoren für die Aktie 76,96 US-Dollar. Heute hat sich im US-amerikanischen Wertpapierhandel... ► Artikel lesen | |
| BIONANO GENOMICS | 3,270 | +3,64 % | Bionano Genomics: Bionano Reports Second Quarter 2025 Results and Highlights Recent Business Progress | SAN DIEGO, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today reported financial results for the second quarter ended June 30, 2025. "We continued to execute on our new... ► Artikel lesen | |
| ASTRIA THERAPEUTICS | 5,900 | +1,72 % | Astria Therapeutics stock price target raised to $26 by JMP on HAE program progress | ||
| AMARIN | 13,500 | -1,46 % | Amarin Corporation plc: Amarin Reports Second Quarter 2025 Financial Results | -- European Partnership with Recordati Established to Maximize VAZKEPA® in Europe; Global Corporate Restructuring Implemented with Anticipated $70 Million in Operating Expense Savings Over Next 12... ► Artikel lesen | |
| OPKO HEALTH | 1,189 | -0,55 % | OPKO Health (OPK) Advances EBV Vaccine and GLP-1 Pipeline While Streamlining Diagnostics | ||
| JAGUAR HEALTH | 1,900 | -6,40 % | Jaguar Health, Inc.: Jaguar Health Family Company Napo Pharmaceuticals to Meet with FDA to Discuss Potential Regulatory Pathways for Crofelemer for Treatment of Ultrarare Pediatric Indication Microvillus Inclusion Disease | As announced, initial proof-of-concept results from the ongoing investigator-initiated trial in Abu Dhabi show crofelemer reduced the required total parenteral nutrition in the first participating MVID... ► Artikel lesen | |
| MALLINCKRODT | - | - | Mallinckrodt plc - 8-K, Current Report |
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu OREXO AB finden Sie auf Wallstreet Online.